Results 271 to 280 of about 102,788 (290)

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies [PDF]

Leukemia & Lymphoma, 2013
Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia.
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Angiogenesis is increased in B-cell chronic lymphocytic leukemia

Blood, 2001
Aguayo and colleagues recently reported elevated levels of vascular endothelial growth factor (VEGF) in the cells of B-cell chronic lymphocytic leukemia (CLL).[1][1] When discussing the possible significance of the elevated VEGF levels in CLL, the authors cite their prior abstract in which ...
Neil E. Kay, LoAnn Peterson, Ameet R. Kini   +2 more
openaire   +3 more sources

Stereotyped B-cell receptors in chronic lymphocytic leukemia

Leukemia & Lymphoma, 2014
Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome.
Kostas Stamatopoulos, Andreas Agathangelidis, Anna Vardi, Panagiotis Baliakas   +3 more
openaire   +2 more sources

Genetic Features of B‐Cell Chronic Lymphocytic Leukemia

Reviews in Clinical and Experimental Hematology, 2000
The genetic features of B‐cell chronic lymphocytic leukemia CLL) are currently being reassessed by molecular cytogenetic techniques such as fluorescence in situ hybridization FISH). Conventional cytogenetic studies by chromosome banding are difficult in CLL mainly because of the low in vitro mitotic activity of the tumor cells, which leads to poor ...
Stephan Stilgenbauer, Peter Lichter, Hartmut Döhner   +2 more
openaire   +3 more sources

Genetics of B-Cell Chronic Lymphocytic Leukemia

2004
B-cell chronic lymphocytic leukemia (B-CLL) is the most frequent type of leukemia among adults in the Western world, with an incidence of about 5 cases per 100,000 residents annually (1,2). The disease affects mainly people of advanced age, but about 20% of patients are younger than 55 (3).B-CLL is characterized by the accumulation of lymphocytes that ...
Hartmut Döhner, Stephan Stilgenbauer, Peter Lichter   +2 more
openaire   +2 more sources

Assessment of a B-cell function in chronic lymphocytic leukemia

Clinical Immunology and Immunopathology, 1976
Abstract Chronic lymphocytic leukemia (CLL) patients were tested for the numbers of T cells, B cells, and cells secreting immunoglobin (Ig) by recently developed methods with antibody coated erythrocytes. Five of seven patients had higher percentages (72–90%) of B cells and lower percentages (4–17%) of T cells than normal controls.
Sheldon Dray, Giuseppe A. Molinaro, William C. Eby, Anthony J. Strelkauskas   +3 more
openaire   +3 more sources

p53 Mutations in B-Cell Chronic Lymphocytic Leukemia

1992
The p53 gene is a nuclear phosphoprotein that can function as a tumor suppressor gene (Michalovitz et al. 1991). Frequent mutations of the p53 gene have been detected in several types of solid tumors including breast (Mackay et al. 1988), colon (Vogelstein et al. 1989), lung (Yokota et al. 1987), liver carcinoma (Hsu et al. 1991), astrocytoma (Fults et
S el Rouby, William Bayona, Elizabeth W. Newcomb, Sobha Pisharody   +3 more
openaire   +3 more sources

B-cell receptor signaling in chronic lymphocytic leukemia

Blood, 2011
AbstractThe B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of chronic lymphocytic leukemia (CLL) have revealed 2 major IgMD-expressing subsets and an isotype-switched variant, each developing from distinct B-cell populations.
Stevenson, FK, Krysov, S, Davies, AJ, Steele, AJ, Packham, G   +4 more
openaire   +4 more sources

Myelomonocytic antigens in B-cell chronic lymphocytic leukemia

Leukemia Research, 1995
The clinical significance of myelomonocytic (MyMo) antigens in B-cell chronic lymphocytic leukemia (B-CLL) is unclear. We have analyzed the expression of MyMo antigens (CD13, CD14 (LeuM3, My4, Mo2), CD15, CD11b, CD11c, CD33 and CD68) on B-lymphocytes (CD19+) in 105 B-CLL patients and in 35 controls.
Neus Villamor, Joan Carles Reverter, Montserrat Rovira, Ciril Rozman, Dolors Tàssies, Emilio Montserrat   +5 more
openaire   +3 more sources

Modulation of apoptosis by cytokines in B‐cell chronic lymphocytic leukemia [PDF]

Cytometry, 1999
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the slow and progressive accumulation of monoclonal apparently mature, CD5(+) B lymphocytes. The majority of circulating cells appear to be nondividing, and it has been suggested that a prolonged life span is mainly responsible for the accumulation of the leukemic cells.
Juan A. Vargas, R.M. Muñoz, Y. Romero, M Briz, Raquel Castejón, A Durántez   +5 more
openaire   +2 more sources